AbbVie announced a $10.9 billion acquisition of Apogee Therapeutics at $135.11 per share in cash, representing a 49.49% premium to Thursday’s close and sending APGE volume to 28.38 million shares against a 1.11 million daily average. The S&P 500 opened +0.12% and the Nasdaq slipp
